The Week Ahead: Fed...
Health Care: Drugs
Acorda Therapeutics Inc. (ACOR: NASDAQ)
$22.07 0.23 | 1.05%
06/04/12 - 02:48 PM ET
Ratio Comparisons
| Company | Industry | S&P 500 | |
| Valuation Ratios | |||
|---|---|---|---|
| P/E Ratio (TTM) | 22.80 | 75.30 | 17.70 |
| P/E High - Last 5 Yrs | n.a. | n.a. | 67.70 |
| P/E Low - Last 5 Yrs | n.a. | n.a. | 12.50 |
| Beta | 0.51 | 0.58 | 0.98 |
| Price to Sales (TTM) | 2.90 | 4.62 | 1.42 |
| Price to Book (MRQ) | 4.00 | 3.44 | 2.41 |
| Price to Tangible Book (MRQ) | 4.17 | 6.74 | 5.08 |
| Price to Cash Flow (TTM) | 17.50 | 26.10 | 9.80 |
| Price to Free Cash Flow (TTM) | 12.00 | 48.80 | 17.40 |
| Dividends | |||
| Dividend Yield (%) | 0.00 | 0.50 | 2.10 |
| Dividend Yield - 5 Yr Avg (%) | n.a. | 0.20 | 2.20 |
| Dividend 5 Yr Growth Rate (%) | n.a. | n.a. | -0.76 |
| Payout Ratio (TTM) | 0.00 | 3.00 | 30.00 |
| Sales (MRQ) vs Qtr 1 Yr Ago (%) | 16.30 | 9.90 | 11.80 |
| Sales (TTM) vs TTM 1 Yr Ago (%) | 53.00 | 7.70 | 9.20 |
| Growth Rates (%) | |||
| Sales - 5 Yr Growth Rate (%) | 57.90 | 9.03 | 1.79 |
| EPS (MRQ) vs Qtr 1 Yr Ago (%) | n.a. | 18.50 | 17.50 |
| EPS (TTM) vs TTM 1 Yr Ago (%) | n.a. | 18.50 | 17.50 |
| EPS - 5 Yr Growth Rate (%) | n.a. | n.a. | -1.66 |
| Capital Spending - 5 Yr Growth Rate (%) | 34.59 | -4.13 | -1.17 |
| Financial Strength | |||
| Quick Ratio (MRQ) | 3.70 | 2.90 | 1.10 |
| Current Ratio (MRQ) | 4.20 | 3.50 | 1.60 |
| LT Debt to Equity (MRQ) | 0.02 | 0.41 | 0.82 |
| Total Debt to Equity (MRQ) | 0.03 | 0.45 | 0.96 |
| Interest Coverage (TTM) | 13.70 | 6.20 | 5.50 |
| Profitability Ratios (%) | |||
| Gross Margin (TTM) | 81.50 | 84.10 | 46.90 |
| Gross Margin - 5 Yr Avg | 83.10 | 83.50 | 47.70 |
| EBITD Margin (TTM) | 18.00 | 27.30 | 18.90 |
| EBITD - 5 Yr Avg | -35.87 | 0.00 | 0.00 |
| Pre-Tax Margin (TTM) | 13.50 | 14.10 | 12.10 |
| Pre-Tax Margin - 5 Yr Avg | -28.20 | 10.60 | 10.30 |
| Management Effectiveness (%) | |||
| Net Profit Margin (TTM) | 0.13 | 0.10 | 0.09 |
| Net Profit Margin - 5 Yr Avg | -28.40 | 5.30 | 7.00 |
| Return on Assets (TTM) | 10.10 | 4.70 | 3.10 |
| Return on Assets - 5 Yr Avg | -12.20 | 2.20 | 2.50 |
| Return on Investment (TTM) | 17.50 | 6.10 | 7.90 |
| Return on Investment - 5 Yr Avg | -22.20 | 2.80 | 6.50 |
| Efficiency | |||
| Revenue/Employee (TTM) | 921,338.00 | 701,747.00 | 449,376.00 |
| Net Income/Employee (TTM) | 119,274.00 | 83,589.00 | 39,003.00 |
| Receivable Turnover (TTM) | 13.30 | 5.80 | 7.60 |
| Inventory Turnover (TTM) | 1.50 | 1.30 | 8.30 |
| Asset Turnover (TTM) | 0.80 | 0.40 | 0.40 |
Portfolios with ACOR
- Portfolio NameUser Type
- ContributorStocks Rising On Unusual Vo...
- ContributorStocks Rising On Unusual Vo...
- Contributor13 Biotech Stocks Bought an...
- Contributor5 Biotech Drug-Launch Stock...
- Usergrandpicks
- UserPART 1 JPMorgan 28th Annual...
- ContributorBarron's Research Reports 3...
- UserUndervalued Biotech's
- UserPART 1 JPMorgan 27th Annual...
- UserFerrengi Holdings
Latest ACOR Headlines from TheStreet
- FDA More Problematic Than Obamacare, Says Acorda CEO
04.24.12 | 06:04 am - BIO CEO Confab Live Blog: Day 2 02.14.12 | 10:02 am
- BIO CEO Conference Live Blog 02.13.12 | 01:02 pm
- 8 Stocks Rising on Huge Volume 01.05.12 | 02:01 pm
- Acorda Rises On Unusually High Volume (ACOR) 11.04.11 | 04:11 pm
- Acorda Stock Hits New 52-Week Low (ACOR) 09.29.11 | 01:09 pm
- SAC Upped Dendreon Exposure Before Blowup 08.15.11 | 05:08 pm
- 5 Biotech Drug-Launch Stocks to Watch 07.18.11 | 09:07 am
- Acorda Stock Gaps Up On Today's Open (ACOR) 05.20.11 | 09:05 am
- European Regulators Approve New Drugs 05.20.11 | 07:05 am
Press Releases for ACOR
- Robbins Umeda LLP Announces An Investigation Of Acorda Therapeutics, Inc. - Business Wire 06.04.12 | 11:06 am
- New Research Presented At 4th Collaborative Meeting Of CMSC And ACTRIMS Expands Understanding Of MS-Related Walking Impairment And Clinical Usage Of AMPYRA® - Business Wire 05.31.12 | 06:05 am
- Acorda Therapeutics Launches First-Ever Online Talk Show Focusing On Walking Problems In Multiple Sclerosis - Business Wire 05.30.12 | 07:05 am
- Acorda Therapeutics Recognized As One Of The Best Places To Work In New York State For Second Consecutive Year - Business Wire 04.30.12 | 07:04 am
- Acorda Therapeutics Presents AMPYRA® Long-Term Safety And Efficacy Data At 64th American Academy Of Neurology Annual Meeting - Business Wire 04.25.12 | 07:04 am
- Acorda Therapeutics Named One Of The 100 Most Trustworthy Companies By Forbes - Business Wire 04.12.12 | 07:04 am
- Acorda Therapeutics To Provide Pipeline Update At Upcoming R&D Day - Business Wire 04.10.12 | 07:04 am
- Acorda Therapeutics Launches New Interactive Website Spotlighting Treatment With Ampyra® (Dalfampridine) Of Walking Problems In Patients With Multiple Sclerosis - Business Wire 04.02.12 | 08:04 am
- Acorda Therapeutics To Present At The Cowen & Company 32nd Annual Health Care Conference - Business Wire 02.27.12 | 07:02 am
- Acorda Therapeutics To Present At 2012 RBC Capital Markets' Global Healthcare Conference - Business Wire 02.22.12 | 06:02 am
Partner Headlines for ACOR
- Revenues Climb at Acorda - Analyst Blog - Zacks 05.04.12 | 06:05 pm
- Zacks #1 Rank Additions for Tuesday - Tale of the Tape - Zacks 04.17.12 | 09:04 am
- Biogen's Fampyra Launched in Canada - Analyst Blog - Zacks 04.13.12 | 06:04 pm
- 4 Compelling Alternatives To Vertex Pharma - Seeking Alpha 02.23.12 | 08:02 am
- 5 Stocks Ripe For A Takeover - Seeking Alpha 10.28.11 | 05:10 pm
- Notable Call Options Activity in Acorda Therapeutics - Benzinga 10.13.11 | 01:10 pm
- Company News for October 6, 2011 - Corporate Summary - Zacks 10.06.11 | 10:10 am
- 7 Possible Biotech Takeover Targets - Seeking Alpha 09.18.11 | 08:09 am
- 5 Biotech Takeover / LBO Targets With Bullish Short Trends - Seeking Alpha 07.15.11 | 07:07 pm
- Zacks #1 Rank Additions for Tuesday - Tale of the Tape - Zacks 07.12.11 | 09:07 am
